WO2006090833A1 - 非ステロイド系消炎鎮痛剤を含有する外用経皮製剤 - Google Patents
非ステロイド系消炎鎮痛剤を含有する外用経皮製剤 Download PDFInfo
- Publication number
- WO2006090833A1 WO2006090833A1 PCT/JP2006/303406 JP2006303406W WO2006090833A1 WO 2006090833 A1 WO2006090833 A1 WO 2006090833A1 JP 2006303406 W JP2006303406 W JP 2006303406W WO 2006090833 A1 WO2006090833 A1 WO 2006090833A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acid
- weight
- parts
- external use
- derivatives
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 49
- 239000000730 antalgic agent Substances 0.000 title abstract description 13
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 title abstract description 9
- -1 diflu-sar Chemical compound 0.000 claims description 69
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims description 41
- 229960000991 ketoprofen Drugs 0.000 claims description 37
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 33
- 239000002253 acid Substances 0.000 claims description 21
- 230000000202 analgesic effect Effects 0.000 claims description 20
- 239000003814 drug Substances 0.000 claims description 12
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical class C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 claims description 10
- 239000004808 2-ethylhexylester Substances 0.000 claims description 6
- XNEFYCZVKIDDMS-UHFFFAOYSA-N avobenzone Chemical compound C1=CC(OC)=CC=C1C(=O)CC(=O)C1=CC=C(C(C)(C)C)C=C1 XNEFYCZVKIDDMS-UHFFFAOYSA-N 0.000 claims description 6
- CNBGNNVCVSKAQZ-UHFFFAOYSA-N benzydamine Chemical compound C12=CC=CC=C2C(OCCCN(C)C)=NN1CC1=CC=CC=C1 CNBGNNVCVSKAQZ-UHFFFAOYSA-N 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- NPSJHQMIVNJLNN-UHFFFAOYSA-N 2-ethylhexyl 4-nitrobenzoate Chemical compound CCCCC(CC)COC(=O)C1=CC=C([N+]([O-])=O)C=C1 NPSJHQMIVNJLNN-UHFFFAOYSA-N 0.000 claims description 5
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 claims description 5
- DXGLGDHPHMLXJC-UHFFFAOYSA-N oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 claims description 5
- 229960001173 oxybenzone Drugs 0.000 claims description 5
- MDKGKXOCJGEUJW-VIFPVBQESA-N (2s)-2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 MDKGKXOCJGEUJW-VIFPVBQESA-N 0.000 claims description 4
- SMFFZOQLHYIRDA-UHFFFAOYSA-N 3,4-dimethoxyphenol Chemical compound COC1=CC=C(O)C=C1OC SMFFZOQLHYIRDA-UHFFFAOYSA-N 0.000 claims description 4
- HORVLKADAZQYRS-UHFFFAOYSA-N 4,4-dimethyl-1-phenylpentane-1,3-dione Chemical class CC(C)(C)C(=O)CC(=O)C1=CC=CC=C1 HORVLKADAZQYRS-UHFFFAOYSA-N 0.000 claims description 4
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims description 4
- MITFXPHMIHQXPI-UHFFFAOYSA-N Oraflex Chemical compound N=1C2=CC(C(C(O)=O)C)=CC=C2OC=1C1=CC=C(Cl)C=C1 MITFXPHMIHQXPI-UHFFFAOYSA-N 0.000 claims description 4
- 150000008366 benzophenones Chemical class 0.000 claims description 4
- NZZIMKJIVMHWJC-UHFFFAOYSA-N dibenzoylmethane Chemical class C=1C=CC=CC=1C(=O)CC(=O)C1=CC=CC=C1 NZZIMKJIVMHWJC-UHFFFAOYSA-N 0.000 claims description 4
- 229960002009 naproxen Drugs 0.000 claims description 4
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims description 4
- 229960004492 suprofen Drugs 0.000 claims description 4
- WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical class [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 claims description 4
- 125000005907 alkyl ester group Chemical group 0.000 claims description 3
- 229960000333 benzydamine Drugs 0.000 claims description 3
- 229960001259 diclofenac Drugs 0.000 claims description 3
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims description 3
- 229960002702 piroxicam Drugs 0.000 claims description 3
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims description 3
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 2
- 229960001671 azapropazone Drugs 0.000 claims description 2
- WOIIIUDZSOLAIW-NSHDSACASA-N azapropazone Chemical compound C1=C(C)C=C2N3C(=O)[C@H](CC=C)C(=O)N3C(N(C)C)=NC2=C1 WOIIIUDZSOLAIW-NSHDSACASA-N 0.000 claims description 2
- 229960005430 benoxaprofen Drugs 0.000 claims description 2
- 230000000903 blocking effect Effects 0.000 claims description 2
- 229940114081 cinnamate Drugs 0.000 claims description 2
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 claims description 2
- 229960001680 ibuprofen Drugs 0.000 claims description 2
- CLMVJORCTWUXKP-UHFFFAOYSA-N 1h-imidazol-2-yl propanoate Chemical compound CCC(=O)OC1=NC=CN1 CLMVJORCTWUXKP-UHFFFAOYSA-N 0.000 claims 1
- KFGVDCBVGNMCJC-UHFFFAOYSA-N 2-hydrazinylbenzoic acid Chemical class NNC1=CC=CC=C1C(O)=O KFGVDCBVGNMCJC-UHFFFAOYSA-N 0.000 claims 1
- CAVUEALRYKNYRW-UHFFFAOYSA-N 3-methylhexane-2,4-dione Chemical compound CCC(=O)C(C)C(C)=O CAVUEALRYKNYRW-UHFFFAOYSA-N 0.000 claims 1
- OVFJGHSGYBVLIJ-UHFFFAOYSA-N OC1=C(C=C(C=C1)OC)C1=CC=CC=2NN=NC21 Chemical compound OC1=C(C=C(C=C1)OC)C1=CC=CC=2NN=NC21 OVFJGHSGYBVLIJ-UHFFFAOYSA-N 0.000 claims 1
- 150000001565 benzotriazoles Chemical class 0.000 claims 1
- HUVYTMDMDZRHBN-UHFFFAOYSA-N drometrizole trisiloxane Chemical compound C[Si](C)(C)O[Si](C)(O[Si](C)(C)C)CC(C)CC1=CC(C)=CC(N2N=C3C=CC=CC3=N2)=C1O HUVYTMDMDZRHBN-UHFFFAOYSA-N 0.000 claims 1
- JSLJCCRWZMDCGG-UHFFFAOYSA-N hexyl 2-[4-(ethylamino)-2-hydroxybenzoyl]benzoate Chemical compound C(CCCCC)OC(C1=C(C=CC=C1)C(C1=C(C=C(C=C1)NCC)O)=O)=O JSLJCCRWZMDCGG-UHFFFAOYSA-N 0.000 claims 1
- 208000024891 symptom Diseases 0.000 abstract description 40
- 230000001900 immune effect Effects 0.000 abstract description 8
- 230000005764 inhibitory process Effects 0.000 abstract description 7
- 210000003491 skin Anatomy 0.000 description 60
- 239000000203 mixture Substances 0.000 description 53
- 238000009472 formulation Methods 0.000 description 32
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 28
- 239000003795 chemical substances by application Substances 0.000 description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- 238000012360 testing method Methods 0.000 description 24
- 238000002156 mixing Methods 0.000 description 23
- 230000003637 steroidlike Effects 0.000 description 21
- 239000000499 gel Substances 0.000 description 19
- 239000011505 plaster Substances 0.000 description 17
- 230000007233 immunological mechanism Effects 0.000 description 16
- 239000006071 cream Substances 0.000 description 14
- 239000000126 substance Substances 0.000 description 14
- 239000002981 blocking agent Substances 0.000 description 13
- 235000014113 dietary fatty acids Nutrition 0.000 description 13
- 239000000194 fatty acid Substances 0.000 description 13
- 229930195729 fatty acid Natural products 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- LVYLCBNXHHHPSB-UHFFFAOYSA-N 2-hydroxyethyl salicylate Chemical compound OCCOC(=O)C1=CC=CC=C1O LVYLCBNXHHHPSB-UHFFFAOYSA-N 0.000 description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 239000000865 liniment Substances 0.000 description 12
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 12
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 12
- 229940040145 liniment Drugs 0.000 description 11
- 239000002674 ointment Substances 0.000 description 11
- 229940079593 drug Drugs 0.000 description 10
- 239000004615 ingredient Substances 0.000 description 10
- 239000003921 oil Substances 0.000 description 10
- 235000019198 oils Nutrition 0.000 description 10
- 210000001165 lymph node Anatomy 0.000 description 9
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 229920000728 polyester Polymers 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 206010070834 Sensitisation Diseases 0.000 description 7
- 150000001298 alcohols Chemical class 0.000 description 7
- DNTGGZPQPQTDQF-XBXARRHUSA-N crotamiton Chemical compound C/C=C/C(=O)N(CC)C1=CC=CC=C1C DNTGGZPQPQTDQF-XBXARRHUSA-N 0.000 description 7
- 229960003338 crotamiton Drugs 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 230000008313 sensitization Effects 0.000 description 7
- 241000723346 Cinnamomum camphora Species 0.000 description 6
- 208000010201 Exanthema Diseases 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000000654 additive Substances 0.000 description 6
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 6
- 229960000846 camphor Drugs 0.000 description 6
- 229930008380 camphor Natural products 0.000 description 6
- 201000005884 exanthem Diseases 0.000 description 6
- 150000004665 fatty acids Chemical class 0.000 description 6
- 229960002389 glycol salicylate Drugs 0.000 description 6
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 6
- 229960001047 methyl salicylate Drugs 0.000 description 6
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 6
- 206010037844 rash Diseases 0.000 description 6
- 229960004889 salicylic acid Drugs 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 229920002125 Sokalan® Polymers 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 229920001577 copolymer Polymers 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- 239000004744 fabric Substances 0.000 description 5
- 229940057995 liquid paraffin Drugs 0.000 description 5
- 230000003472 neutralizing effect Effects 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 239000004698 Polyethylene Substances 0.000 description 4
- 239000001361 adipic acid Substances 0.000 description 4
- 235000011037 adipic acid Nutrition 0.000 description 4
- 229910052782 aluminium Inorganic materials 0.000 description 4
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 4
- 229940031578 diisopropyl adipate Drugs 0.000 description 4
- 239000003349 gelling agent Substances 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 229940041616 menthol Drugs 0.000 description 4
- 230000005012 migration Effects 0.000 description 4
- 238000013508 migration Methods 0.000 description 4
- 229960001679 octinoxate Drugs 0.000 description 4
- 239000004006 olive oil Substances 0.000 description 4
- 229920000573 polyethylene Polymers 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 229920001296 polysiloxane Polymers 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 229940116351 sebacate Drugs 0.000 description 4
- CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- CMBYOWLFQAFZCP-UHFFFAOYSA-N Hexyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCCCCC CMBYOWLFQAFZCP-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 231100000220 OECD 429 (LLNA) Skin Sensitisation Toxicity 0.000 description 3
- 239000004743 Polypropylene Substances 0.000 description 3
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 125000003354 benzotriazolyl group Chemical class N1N=NC2=C1C=CC=C2* 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 229960000541 cetyl alcohol Drugs 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 3
- 229940100463 hexyl laurate Drugs 0.000 description 3
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 3
- 238000011419 induction treatment Methods 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000004745 nonwoven fabric Substances 0.000 description 3
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 3
- 239000003883 ointment base Substances 0.000 description 3
- 235000019271 petrolatum Nutrition 0.000 description 3
- 239000004584 polyacrylic acid Substances 0.000 description 3
- 229920006267 polyester film Polymers 0.000 description 3
- 229920001155 polypropylene Polymers 0.000 description 3
- 229910052710 silicon Inorganic materials 0.000 description 3
- 239000010703 silicon Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- ZNWWKYGEXUDHCX-UHFFFAOYSA-N 10-decoxy-10-oxodecanoic acid Chemical compound CCCCCCCCCCOC(=O)CCCCCCCCC(O)=O ZNWWKYGEXUDHCX-UHFFFAOYSA-N 0.000 description 2
- KNENSDLFTGIERH-UHFFFAOYSA-N 2,2,4,4-tetramethyl-3-phenylpentan-3-ol Chemical class CC(C)(C)C(O)(C(C)(C)C)C1=CC=CC=C1 KNENSDLFTGIERH-UHFFFAOYSA-N 0.000 description 2
- GOXQRTZXKQZDDN-UHFFFAOYSA-N 2-Ethylhexyl acrylate Chemical compound CCCCC(CC)COC(=O)C=C GOXQRTZXKQZDDN-UHFFFAOYSA-N 0.000 description 2
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical class OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- UUGLJVMIFJNVFH-UHFFFAOYSA-N Hexyl benzoate Chemical compound CCCCCCOC(=O)C1=CC=CC=C1 UUGLJVMIFJNVFH-UHFFFAOYSA-N 0.000 description 2
- 239000004166 Lanolin Substances 0.000 description 2
- 235000021360 Myristic acid Nutrition 0.000 description 2
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- 206010034972 Photosensitivity reaction Diseases 0.000 description 2
- 229920001328 Polyvinylidene chloride Polymers 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical class CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 2
- 239000006096 absorbing agent Substances 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 150000005215 alkyl ethers Chemical class 0.000 description 2
- 150000005417 aminobenzoic acid derivatives Chemical class 0.000 description 2
- 230000001760 anti-analgesic effect Effects 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical compound [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 125000002573 ethenylidene group Chemical group [*]=C=C([H])[H] 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- OIKBVOIOVNEVJR-UHFFFAOYSA-N hexadecyl 6-methylheptanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCC(C)C OIKBVOIOVNEVJR-UHFFFAOYSA-N 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- 229940039717 lanolin Drugs 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 229940060184 oil ingredients Drugs 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 238000001782 photodegradation Methods 0.000 description 2
- 230000036211 photosensitivity Effects 0.000 description 2
- 208000017983 photosensitivity disease Diseases 0.000 description 2
- 231100000434 photosensitization Toxicity 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 229920000346 polystyrene-polyisoprene block-polystyrene Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 229920002689 polyvinyl acetate Polymers 0.000 description 2
- 239000011118 polyvinyl acetate Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 229940077082 red pepper extract Drugs 0.000 description 2
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical class CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229960001017 tolmetin Drugs 0.000 description 2
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000003871 white petrolatum Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 1
- GUHPRPJDBZHYCJ-SECBINFHSA-N (2s)-2-(5-benzoylthiophen-2-yl)propanoic acid Chemical compound S1C([C@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CC=C1 GUHPRPJDBZHYCJ-SECBINFHSA-N 0.000 description 1
- AFDXODALSZRGIH-QPJJXVBHSA-N (E)-3-(4-methoxyphenyl)prop-2-enoic acid Chemical compound COC1=CC=C(\C=C\C(O)=O)C=C1 AFDXODALSZRGIH-QPJJXVBHSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- BNXZHVUCNYMNOS-UHFFFAOYSA-N 1-butylpyrrolidin-2-one Chemical compound CCCCN1CCCC1=O BNXZHVUCNYMNOS-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- HFZLSTDPRQSZCQ-UHFFFAOYSA-N 1-pyrrolidin-3-ylpyrrolidine Chemical compound C1CCCN1C1CNCC1 HFZLSTDPRQSZCQ-UHFFFAOYSA-N 0.000 description 1
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- 239000000263 2,3-dihydroxypropyl (Z)-octadec-9-enoate Substances 0.000 description 1
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 1
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- IOHPVZBSOKLVMN-UHFFFAOYSA-N 2-(2-phenylethyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1CCC1=CC=CC=C1 IOHPVZBSOKLVMN-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- KRYAMNIMTZFVDF-UHFFFAOYSA-N 2-[methoxy-(2-methoxyphenyl)methylidene]imidazolidine-4,5-dione Chemical compound COC1=C(C(=C2NC(C(N2)=O)=O)OC)C=CC=C1 KRYAMNIMTZFVDF-UHFFFAOYSA-N 0.000 description 1
- GUHQWKGQAYBNEW-UHFFFAOYSA-N 2-ethylhexyl propanoate Chemical compound CCCCC(CC)COC(=O)CC GUHQWKGQAYBNEW-UHFFFAOYSA-N 0.000 description 1
- XULHFMYCBKQGEE-UHFFFAOYSA-N 2-hexyl-1-Decanol Chemical compound CCCCCCCCC(CO)CCCCCC XULHFMYCBKQGEE-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- HIPQTCQUXOFTFI-UHFFFAOYSA-N 2-methoxy-1,3-diphenylpropane-1,3-dione Chemical compound C=1C=CC=CC=1C(=O)C(OC)C(=O)C1=CC=CC=C1 HIPQTCQUXOFTFI-UHFFFAOYSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- BGRXBNZMPMGLQI-UHFFFAOYSA-N 2-octyldodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCCCC BGRXBNZMPMGLQI-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- DISYHRKLFBBFAS-UHFFFAOYSA-N 3-(1-methyl-4-propan-2-ylcyclohexyl)oxypropane-1,2-diol Chemical compound CC(C)C1CCC(C)(OCC(O)CO)CC1 DISYHRKLFBBFAS-UHFFFAOYSA-N 0.000 description 1
- RZRNAYUHWVFMIP-GDCKJWNLSA-N 3-oleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-GDCKJWNLSA-N 0.000 description 1
- ALYNCZNDIQEVRV-PZFLKRBQSA-N 4-amino-3,5-ditritiobenzoic acid Chemical compound [3H]c1cc(cc([3H])c1N)C(O)=O ALYNCZNDIQEVRV-PZFLKRBQSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 244000043261 Hevea brasiliensis Species 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000006002 Pepper Substances 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 241000722363 Piper Species 0.000 description 1
- 235000016761 Piper aduncum Nutrition 0.000 description 1
- 235000017804 Piper guineense Nutrition 0.000 description 1
- 235000008184 Piper nigrum Nutrition 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- TVQZAMVBTVNYLA-UHFFFAOYSA-N Pranoprofen Chemical compound C1=CC=C2CC3=CC(C(C(O)=O)C)=CC=C3OC2=N1 TVQZAMVBTVNYLA-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 239000005844 Thymol Chemical class 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229920000800 acrylic rubber Polymers 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- KLMDYFUUSKOJAX-UHFFFAOYSA-K aluminum;acetate;dihydroxide Chemical compound CC(=O)O[Al](O)O KLMDYFUUSKOJAX-UHFFFAOYSA-K 0.000 description 1
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 1
- 235000010407 ammonium alginate Nutrition 0.000 description 1
- 239000000728 ammonium alginate Substances 0.000 description 1
- KPGABFJTMYCRHJ-YZOKENDUSA-N ammonium alginate Chemical compound [NH4+].[NH4+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O KPGABFJTMYCRHJ-YZOKENDUSA-N 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- WXBLLCUINBKULX-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1.OC(=O)C1=CC=CC=C1 WXBLLCUINBKULX-UHFFFAOYSA-N 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical group C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- WXNRYSGJLQFHBR-UHFFFAOYSA-N bis(2,4-dihydroxyphenyl)methanone Chemical compound OC1=CC(O)=CC=C1C(=O)C1=CC=C(O)C=C1O WXNRYSGJLQFHBR-UHFFFAOYSA-N 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 229940078456 calcium stearate Drugs 0.000 description 1
- 239000010495 camellia oil Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 150000001851 cinnamic acid derivatives Chemical class 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- 229940031569 diisopropyl sebacate Drugs 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 description 1
- XFKBBSZEQRFVSL-UHFFFAOYSA-N dipropan-2-yl decanedioate Chemical compound CC(C)OC(=O)CCCCCCCCC(=O)OC(C)C XFKBBSZEQRFVSL-UHFFFAOYSA-N 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 229940120889 dipyrone Drugs 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- MDKXBBPLEGPIRI-UHFFFAOYSA-N ethoxyethane;methanol Chemical compound OC.CCOCC MDKXBBPLEGPIRI-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 1
- 229960001347 fluocinolone acetonide Drugs 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- LHGVFZTZFXWLCP-UHFFFAOYSA-N guaiacol Chemical compound COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- QAKXLTNAJLFSQC-UHFFFAOYSA-N hexadecyl tetradecanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCC QAKXLTNAJLFSQC-UHFFFAOYSA-N 0.000 description 1
- 239000012943 hotmelt Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229960002373 loxoprofen Drugs 0.000 description 1
- BAZQYVYVKYOAGO-UHFFFAOYSA-M loxoprofen sodium hydrate Chemical compound O.O.[Na+].C1=CC(C(C([O-])=O)C)=CC=C1CC1C(=O)CCC1 BAZQYVYVKYOAGO-UHFFFAOYSA-M 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229940105112 magnesium myristate Drugs 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- DMRBHZWQMKSQGR-UHFFFAOYSA-L magnesium;tetradecanoate Chemical compound [Mg+2].CCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCC([O-])=O DMRBHZWQMKSQGR-UHFFFAOYSA-L 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 150000002689 maleic acids Chemical class 0.000 description 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
- 150000004667 medium chain fatty acids Chemical class 0.000 description 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- 229960001929 meloxicam Drugs 0.000 description 1
- DJGAAPFSPWAYTJ-UHFFFAOYSA-M metamizole sodium Chemical compound [Na+].O=C1C(N(CS([O-])(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 DJGAAPFSPWAYTJ-UHFFFAOYSA-M 0.000 description 1
- 125000005397 methacrylic acid ester group Chemical group 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- RZRNAYUHWVFMIP-UHFFFAOYSA-N monoelaidin Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-UHFFFAOYSA-N 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229940078812 myristyl myristate Drugs 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 229920003052 natural elastomer Polymers 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229920001194 natural rubber Polymers 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229940073665 octyldodecyl myristate Drugs 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- BARWIPMJPCRCTP-UHFFFAOYSA-N oleic acid oleyl ester Natural products CCCCCCCCC=CCCCCCCCCOC(=O)CCCCCCCC=CCCCCCCCC BARWIPMJPCRCTP-UHFFFAOYSA-N 0.000 description 1
- BARWIPMJPCRCTP-CLFAGFIQSA-N oleyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC BARWIPMJPCRCTP-CLFAGFIQSA-N 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229960002739 oxaprozin Drugs 0.000 description 1
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
- 150000002942 palmitic acid derivatives Chemical class 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 229940116257 pepper extract Drugs 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 230000000886 photobiology Effects 0.000 description 1
- 238000006552 photochemical reaction Methods 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920001083 polybutene Polymers 0.000 description 1
- 229920001195 polyisoprene Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229960003101 pranoprofen Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 1
- 239000000770 propane-1,2-diol alginate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 239000000473 propyl gallate Chemical class 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 229940032159 propylene carbonate Drugs 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 229920002050 silicone resin Polymers 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- BTURAGWYSMTVOW-UHFFFAOYSA-M sodium dodecanoate Chemical compound [Na+].CCCCCCCCCCCC([O-])=O BTURAGWYSMTVOW-UHFFFAOYSA-M 0.000 description 1
- 229940082004 sodium laurate Drugs 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 229920000468 styrene butadiene styrene block copolymer Polymers 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229960002871 tenoxicam Drugs 0.000 description 1
- LZNWYQJJBLGYLT-UHFFFAOYSA-N tenoxicam Chemical compound OC=1C=2SC=CC=2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 LZNWYQJJBLGYLT-UHFFFAOYSA-N 0.000 description 1
- DZKXJUASMGQEMA-UHFFFAOYSA-N tetradecyl tetradecanoate Chemical compound CCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCC DZKXJUASMGQEMA-UHFFFAOYSA-N 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 229960001312 tiaprofenic acid Drugs 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229930003799 tocopherol Chemical class 0.000 description 1
- 239000011732 tocopherol Chemical class 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- ILJSQTXMGCGYMG-UHFFFAOYSA-N triacetic acid Chemical compound CC(=O)CC(=O)CC(O)=O ILJSQTXMGCGYMG-UHFFFAOYSA-N 0.000 description 1
- GAAKLDANOSASAM-UHFFFAOYSA-N undec-10-enoic acid;zinc Chemical compound [Zn].OC(=O)CCCCCCCCC=C GAAKLDANOSASAM-UHFFFAOYSA-N 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 229940098697 zinc laurate Drugs 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
- 229940057977 zinc stearate Drugs 0.000 description 1
- 229940118257 zinc undecylenate Drugs 0.000 description 1
- GPYYEEJOMCKTPR-UHFFFAOYSA-L zinc;dodecanoate Chemical compound [Zn+2].CCCCCCCCCCCC([O-])=O.CCCCCCCCCCCC([O-])=O GPYYEEJOMCKTPR-UHFFFAOYSA-L 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical class OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
- A61K8/445—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof aromatic, i.e. the carboxylic acid directly linked to the aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
- A61K8/466—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfonic acid derivatives; Salts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Definitions
- Topical transdermal preparation containing non-steroidal anti-inflammatory analgesic containing non-steroidal anti-inflammatory analgesic
- the present invention relates to a transdermal preparation for external use containing a non-steroidal anti-inflammatory analgesic.
- Non-steroidal anti-inflammatory analgesics such as ketoprofen have excellent anti-inflammatory action and analgesic action, so patches such as poultices and plasters, gels, creams, ointments, and remedies It is contained as a medicinal ingredient in various forms of transdermal preparations for external use.
- patches such as poultices and plasters, gels, creams, ointments, and remedies It is contained as a medicinal ingredient in various forms of transdermal preparations for external use.
- some of the non-steroidal anti-inflammatory analgesic transdermal preparations are photosensitivity, and in rare cases, develop skin symptoms due to non-immunological or immunological mechanisms when exposed to excessive light. Reported to have potential!
- Patent Document 1 Japanese Patent Laid-Open No. 60-155111
- Patent Document 2 International Publication No. 01Z68061 Pamphlet
- Patent Document 3 JP-A-9 169658
- Patent Document 4 JP-A 53-99316
- Patent Document 5 Japanese Patent Laid-Open No. 56-22711
- Patent Document 6 Japanese Unexamined Patent Publication No. 2000-136122
- Non-Patent Document 1 Journal of the Japanese Dermatological Association, 113 (4), 405-411 (2003)
- Non-Patent Document 2 Photochemistry and photobiology, 73 (2), 119-27 (2001)
- An object of the present invention is to more reliably prevent skin symptoms derived from light-irradiated skin preparations in a transdermal preparation for external use containing a light-sensitive non-steroidal anti-inflammatory analgesic. Means for solving the problem
- the inventors of the present invention are diligently studying to achieve the above-mentioned object.
- active oxygen generated when the drug is irradiated with sunlight is applied to tissues and cells.
- Some are caused by non-immunological mechanisms that cause injury, and some drugs that are hapten by exposure to excessive sunlight cause damage to tissues' cells via the immunological mechanism.
- Non-Patent Documents 1 and 2 Based on the knowledge (for example, see Non-Patent Documents 1 and 2) that skin symptoms derived from photosensitive drugs are caused by ultraviolet rays, particularly UVA (wavelength: 320 to 400 nm). Attempts were made to add various UVA blockers to the drug product, but not all UVA blockers were effective in preventing the above skin symptoms. It was also a force that existed. Therefore, as a result of further research, surprisingly, among UV blockers including UVA blockers and UVB blockers, those having good skin migration properties are considered to constitute the above skin symptoms. It has been found that the method is particularly effective in suppressing both immune symptoms and immune symptoms, and the present invention has been completed. It has never been known that the skin transferability of UV blocking agents is involved in the suppression of the above skin symptoms, and the powerful effect of the present invention is far beyond the expectation of those skilled in the art.
- the present invention relates to a transdermal preparation for external use containing a light-sensitive non-steroidal anti-inflammatory analgesic agent and a UV blocking agent having a high skin migration property.
- the non-steroidal anti-inflammatory analgesic agent is ketoprofen, thiaprofenic acid, suprofen, tolmethine, canoleprofen, beoxaprofen, piroxicam, benzydamine, naproxen, diclofenac, ibuprofen, diflusar, azapropazole, And the above-mentioned external skin, selected from the group consisting of pharmaceutically acceptable salts thereof Relates to the formulation.
- the UV blocking agent is a dibenzoylmethane derivative or a benzophenone derivative.
- the present invention relates to the above-mentioned transdermal preparation for external use selected from the group consisting of a cinnamate derivative, a camphor derivative, a benzotriazole derivative, an amino acid compound, a benzoylpinacolone derivative, and an aminobenzoic acid derivative.
- the present invention relates to UV blocking power 4-tert-butyl-4'-methoxydibenzoylmethane, 2- (4-jetylamino-2-hydroxybenzoyl) benzoic acid n-hexyl ester, 4 —Hydroxy-1-3-methoxy cinnamate, 4-hydroxy-1-3-methoxy cinnamate, branched alkyl ester, terephthalylidene 3, 3, -dicamphor 10, 10, 1-disulfonic acid, 2- (2H-benzotriazole—2— ) —4—Methyl—6— [2—methyl 3— [1, 3, 3, 3—tetramethyl— 1— [(trimethylsilyl) oxy] disiloxane] propyl] phenol, dimethoxybenzylidene dioxoimidazo Lysine propionic acid 2 —ethylhexyl ester, 1— (3,4 dimethoxyphenol) — 4,
- the expression of light-induced skin symptoms by a light-sensitive non-steroidal anti-inflammatory analgesic is remarkably suppressed. That is, in the present invention, the generation of active oxygen and free radicals from the photosensitive drug, the hapteniness of the drug, etc., which are the cause of the skin symptom, are effectively suppressed by the UV blocker having high skin migration. Be done
- the UV blocker should be transferred to the skin together with a light-sensitive nonsteroidal anti-inflammatory analgesic. Therefore, it is considered that the above symptoms are effectively suppressed by suppressing the photochemical reaction of the anti-inflammatory analgesic agent not only in the preparation but also in the skin.
- Patent Document 6 describes an external preparation for skin containing an ultraviolet protective agent such as paramethoxyketic acid-2-ethylhexyl, an anti-inflammatory agent such as indomethacin, and a metal chelating agent.
- the transdermal preparation for external use of the present invention can exert an anti-inflammatory analgesic effect while sufficiently preventing the occurrence of a skin symptom derived from a photosensitive drug caused by a non-immunological or immunological mechanism. Therefore, it is expected to be applied as a highly safe pharmaceutical product.
- the transdermal preparation for external use of the present invention is characterized by containing a light-sensitive nonsteroidal anti-inflammatory analgesic agent and a UV blocking agent having a high skin migration property.
- the UV blocking agent used in the transdermal preparation for external use of the present invention preferably has a high skin transferability, and more preferably has a high storage property in the stratum corneum. Therefore, the UV blocker used in the preparation of the present invention is a dibenzoylmethane derivative, a benzophenone derivative, a cinnamic acid derivative, a camphor derivative, a benzotriazole derivative, an amino acid compound, a benzoylpinacolone having an attractive property. It may be an organic UV blocker such as a derivative or an aminobenzoic acid derivative.
- the amount of UV blocking agent transferred to the skin is determined by spreading a piece of skin collected from a hairless mouse or the like on a filter paper moistened with a physiological solution such as physiological saline, and applying the test substance to the skin piece. Apply and leave for a predetermined time, for example, 4 to 8 hours, typically about 6 hours, then cut out a predetermined area of the skin piece around the test substance application part and remove the remaining test substance on the skin surface Therefore, it can be measured by quantifying the amount of the test substance in the skin.
- the blending amount of the UV blocking agent in the external transdermal preparation of the present invention is not particularly limited, but is preferably 0.01 to 20% by weight based on the total amount of the preparation, and preferably 1 to 10% by weight. Further preferred is 2 to 5% by weight. If the blending amount of the UV blocking agent is not less than the lower limit, the skin symptom is effectively suppressed, and if it is not more than the upper limit, an undesirable reaction can be avoided.
- “suppress” refers to a numerical value relating to a skin symptom caused by a non-immunological mechanism evaluated by an auricle light irradiation test (see Experimental Example 1) by containing a UV blocker, and Figures related to skin symptoms due to immunological mechanisms evaluated in local lymph node tests (see Experimental Examples 2 and 4), skin photosensitization tests (see Experimental Example 3), etc. do not contain the above UV blockers. , It means that it will decrease! Degree of reduction (suppression rate) is preferably 4% or more, more preferably 30% More preferably, it is 50% or more, and most preferably 60% or more.
- the present invention more reliably prevents skin symptoms caused by a non-immunological or immunological mechanism in a topical transdermal preparation containing a light-sensitive nonsteroidal anti-inflammatory analgesic as a medicinal ingredient. It is to prevent.
- a non-steroidal anti-inflammatory analgesic is not particularly limited as long as it has photosensitivity, and more typically can cause the above skin symptoms upon light irradiation.
- ketoprofen For example, ketoprofen, Thiaprofenic acid, suprofen, flurbiprofen, loxoprofen, tolmetine, canoleprofen, benoxaprofen, piroxicam, benzydamine, naproxen, diclofenac, ibubufen, diflunisal, azapropazone, ferrovinac, methyl salicylate, glycol salicylate Celecoxib, oral fuecoxib, acetaminophen, mefenamic acid, clophezone, sulpyrine, aluminoprofen, naproxen, pranoprofen, mepyrazole, oxaprozin, tenoxicam, Runokishikamu, meloxicam Contact and Z or include their pharmaceutically acceptable salts, ketoprofen having Benzofue non similar framework inter alia structure, tiaprofenic acid, suprofen, particularly preferably ketoprofen to
- the amount of the nonsteroidal anti-inflammatory analgesic in the external transdermal preparation of the present invention is not particularly limited, but is preferably 0.1 to 10% by weight based on the total amount of the preparation. If the amount of the non-steroid anti-inflammatory analgesic is at least the above lower limit, a good anti-inflammatory analgesic effect can be obtained.
- UV blockers and non-steroidal anti-inflammatory analgesics include, but are not limited to, for example, 4-tert-butyl 4,1 methoxydibenzoylmethane, 2- (2,1 hydroxy 5'— Methoxyphenyl) monobenzotriazole, terephthalylidene 3, 3, -dicampin-- 10, 10, 10-disulfonic acid, oxybenzone, 4-aminobenzoic acid ethyl ester and 4-methoxykeynic acid 2-ethylhexyl ester Examples include combinations of one or more selected UV blockers with ketoprofen.
- 4-tert-butyl-4-methoxydibenzoylmethane, terephthalylidene More than a combination of ketoprofen with one or more UV blockers selected from the group consisting of 3, 3, -dicamphor 10, 10, monodisulfonic acid, oxybenzone and 4-aminobenzoic acid ethyl ester
- the preferred combination of 4-tert-butyl-4′-methoxydibenzoylmethane and ketoprofen is particularly preferred.
- 2, 2 ′, 4, 4′-tetrahydroxybenzophenone, 4-aminobenzoic acid, and ethylene glycol monosalicylate which are UV blockers described in Patent Document 6, exacerbate the above skin symptoms. In the present invention, it is not preferable to combine with ketoprofen.
- each formulation is prepared according to the dosage form of the preparation. It is preferable that a base is contained.
- the dosage form of the transdermal preparation for external use of the present invention include patches such as poultices or plasters, gels, creams, ointments, liniments, etc.
- nonsteroidal anti-inflammatory analgesics A patch excellent in absorbability is preferred from the viewpoint of the good effects of the present invention.
- the poultice base used in the poultice of the present invention is not particularly limited and is selected from those usually used.
- the components contained in such a poultice base include, for example, thickeners (polyacrylic acid soda, polyacrylic acid, polyvinyl alcohol, polybulurpyrrolidone, polyethylene oxide, polybulurmethacrylate, etc.).
- Molecules natural products such as gum arabic, starch, gelatin, methylcellulose, hydroxypropylcellulose, alginic acid, sodium alginate, ammonium alginate, sodium carboxymethylcellulose, etc., wetting agents (urea, glycerin, polyethylene glycol, propylene glycol) , Butyleneglycanol, sorbitol, etc.
- Fillers (kaolin, talc, bennite, epoxy coffins, organic acids (taenoic acid, tartaric acid, maleic acid, maleic anhydride, succinic acid, etc.), calcium, magnesium, aluminum, etc.), water, solubilizer ( Propylene carbonate, crotamiton, diisopropyl adipate, etc.), rash inhibitor (diphenhydramine hydrochloride, chlorfelamin maleate, glycyrrhizic acid, dexamethasone, betamethasone, fluocinolone acetonide, etc.), other additives (sali And selected from among them, for example, tylic acid, methyl salicylate, glycol salicylate, 1 menthol, camphor, norlic acid ⁇ -rilamide, red pepper extract, hearth oil, Aison (registered trademark), etc.
- the poultice of the present invention can be obtained by blending the above-mentioned essential components into the poul
- a preferred production example (formulation example) of a poultice is shown. That is, first, 0.1 to 10 parts by weight of the non-steroid anti-inflammatory analgesic agent and 0.01 to 20 parts by weight of the UV blocking agent are mixed and dissolved in 0.5 to 8 parts by weight of a solubilizing agent to obtain a uniform mixture. Get A. On the other hand, 5 to 20 parts by weight (preferably 10 to 15 parts by weight) of a thickener is mixed and dispersed in 5 to 40 parts by weight of a wetting agent and 10 to 80 parts by weight of water, and further 20 parts by weight or less of a filler is added. And obtain a uniform kneaded product B.
- the mixture A is added to the kneaded material B and mixed to obtain a uniform kneaded material.
- the obtained kneaded material is spread coated on a support by a usual method, and then a release coating is applied thereon to obtain the poultice of the present invention.
- a stretchable or non-stretchable support can be used.
- the strong support include cloth, non-woven fabric, polyurethane, polyester, poly (vinyl acetate), poly (vinylidene chloride), polyethylene, polyethylene terephthalate, aluminum sheet, or a composite material thereof.
- Be Examples of the release coating include polyethylene, polypropylene, polyvinyl chloride, polyester, polysalt vinylidene, and a material having a silicone strength paper strength.
- the blaster base used in the plaster of the present invention is not particularly limited and is selected from those commonly used.
- Examples of the components contained in such a plaster base include, for example, a polymer base (acrylic acid which is a copolymer with a butyl monomer such as esters of methacrylic acid ester, acrylonitrile, butyl acetate, butyl propionate).
- composition silicone resin, polyisoprene rubber, natural rubber, acrylic rubber, styrene-butadiene-styrene block copolymer, styrene-isoprene-styrene block copolymer), fat or higher fatty acid (almond oil, olive oil, etc.) Oil, camellia oil, persic oil, lacquer oil, oleic oil, liquid paraffin, polybutene, etc.), tackifier (rosin, rosin-modified maleic acid, hydrogenated rosin ester, etc.), fatty acid metal salt (zinc undecylenate, Zinc stearate, calcium stearate, aluminum stearate, stearin Magnesium oxide, sodium stearate, zinc normitate, myristic Zinc acid, magnesium myristate, sodium laurate, zinc laurate, etc., anti-rash agent, other additives (salicylic acid, methyl salicylate, glycol salicylate,
- a preferred production example (formulation example) of a plaster agent is shown. That is, first, in the case of producing by a hot melt method, first, using a mixer such as a kneader or a mixer, 120 to 160 ° C, 5 to 40 parts by weight of the polymer base, 20 to 70 weights of the oil or fat or higher fatty acid. Parts, 10 to 40 parts by weight of the tackifier and 0.1 to 10 parts by weight of the fatty acid metal salt, and then the non-steroidal anti-inflammatory analgesic agent 0.1 to 10 parts by weight of the UV blocker. 0. 1 to 20 parts by weight are added and mixed.
- a mixer such as a kneader or a mixer
- the obtained mixture is spread directly on the support, or on a paper, film or the like that has been subjected to a release treatment, and then stretched and then crimped so as to cover the desired support. It may be transferred.
- the above components are dissolved in a solvent such as toluene, hexane, methylene chloride using a mixer such as an explosion-proof mixer, and the resulting solution is subjected to mold release treatment.
- the film is spread on a sheet of paper, film, etc., the solvent is distilled off with a dryer, and then the film is pressure-transferred with the desired support covered.
- the plaster agent of the present invention is obtained by applying a release coating on the spread coating on the support.
- the support examples include cloth, nonwoven fabric, polyurethane, polyester, poly (vinyl acetate), poly (vinylidene chloride), polyethylene, polyethylene terephthalate, aluminum sheet, and those that can also be used as a composite material. It is done.
- the release coating include polyethylene, polypropylene, polychlorinated butyl, polyester, polysalt vinylidene, and those that have a silicone strength paper strength.
- the ointment base used in the ointment of the present invention is not particularly limited, and is selected from those usually used.
- the components contained in such an ointment base include, for example, higher fatty acids or their esters (adipic acid, myristic acid, palmitic acid, stearic acid, oleic acid, adipic acid ester, myristic acid ester, palmitic acid Esters, decyl sebacate, hexyl laurate, isoota Cetyl titanate), waxes (whale wax, beeswax, ceresin, etc.), surfactants (polyoxyethylene alkyl ether phosphates, etc.), higher alcohols (cetanol, stearyl alcohol, cetostearyl alcohol, etc.), silicone oil (dimethyl) Polysiloxane, methyl vinyl polysiloxane, glycol methyl polysiloxane,
- the gel base used in the gel of the present invention is not particularly limited and is selected from those usually used.
- the components contained in such a gel base include, for example, lower alcohols (ethanol, isopropanol, etc.), water, gelling agents (carboxybule polymer, hydroxyethyl cellulose, hydroxypropyl senorelose, methinoresenolellose, Ethinoresenorelose, canoleboxymethylenosesenolose, propylene glycol ester of arginate, etc.), neutralizing agents (triethanolamine, diisopronono V-lamine, sodium hydroxide, etc.), surfactants ( Sorbitan sesquioleate, sorbitan trioleate, sorbitan monooleate, sorbitan monostearate, sorbitan monolaurate, polyethylene glycol monostearate, polyoxyethylene methanol ether, polyoxyethylene cetyl ether, Polyoxyethylene laureate ether,
- a preferred production method (formulation example) of the gel is shown. That is, first, 0.5 to 5 parts by weight of a gelling agent is added to 55 parts by weight or less of water and swollen to obtain a swollen product A. On the other hand, 0.1 to 10 parts by weight of the non-steroidal anti-inflammatory analgesic agent and 0.01 to 20 parts by weight of the UV blocker are dissolved or suspended in 0.1 part by weight of a dissolving agent, and this is further dissolved in glycol. Dissolve B in a mixture of no more than 40 parts by weight and no more than 60 parts by weight of lower alcohol. Next, after adding the dissolved material B to the swollen material A, the gel agent of the present invention is obtained by adding a neutralizing agent and adjusting the pH value to be ⁇ 7.
- the cream base used in the cream of the present invention is not particularly limited, and is selected from those usually used.
- components contained in such a cream base include higher fatty acid esters (such as adipic acid ester, myristic acid ester, palmitic acid ester, decyl sebacate, hexyl laurate, cetyl isooctanoate), lower Alcohol (ethanol, isopropanol, etc.), carbohydrates (liquid paraffin, squalane, etc.), polyhydric alcohols (propylene glycol, 1, 3 butylene glycol, etc.), higher alcohols (2 hexyl decanol, cetanol, 2-octyldodecanol, etc.), milking agents (polyoxyethylene alkyl ethers, fatty acid esters, polyethylene glycol fatty acid esters, etc.) ), Preservatives (such as paraoxy benzoates), absorption enhancers (such as propylene carbon
- a gelling agent carboxymethylcellulose, propylene glycol alginate, etc.
- neutralizing agents triethanolamine, diisoprono V-lamine, sodium hydroxide, etc.
- a preferred production example (formulation example) of a gel cream is shown. That is, first, 0.1 to 10 parts by weight of the non-steroidal anti-inflammatory analgesic agent and 0.01 to 20 parts by weight of the UV blocker are dissolved in a mixture of 25 parts by weight or less of a higher fatty acid ester and 40 parts by weight or less of a lower alcohol. Further, 0.5 parts by weight or less of an antiseptic and 5 parts by weight or less of an emulsifier are added to obtain a mixture A. On the other hand, a swelling agent B is obtained by adding a gelling agent to water so as to have a concentration of 0.5 to 5 parts by weight and allowing the mixture to swell.
- the swollen material B is mixed with the mixture A and uniformly emulsified with a homomixer, and then the resulting emulsion is adjusted to have a pH value of ⁇ 8 by adding a neutralizing agent.
- the gel cream of the invention is obtained.
- the liniment base used in the liniment of the present invention is not particularly limited, and is selected from those usually used.
- components contained in such a liniment base include alcohols (monohydric alcohols such as ethanol, propanol and isopropanol, polyhydric alcohols such as polyethylene glycol, propylene glycol and butylene glycol).
- the liniment of the present invention is obtained by adding 0.1 to 10 parts by weight of the non-steroid anti-inflammatory analgesic agent and 0.01 to 20 parts by weight of the UV blocker to such a liniment base. be able to.
- a neutralizing agent for adjusting the pH if necessary!
- a viscosity-imparting agent such as methylcellulose, an anti-rash agent, and other additives (salicylic acid, salicylic acid). Methyl, glycol salicylate, 1 menthol, camphor, pepper oil, pepper extract, norlic acid lylamide, crotamiton, Aison (registered trademark), propylene carbonate, diisopropyl adipate, etc.) may be added.
- the above formulation examples and production methods are merely examples, and the liniment of the present invention can of course be obtained by known liniment production methods. Also in the blending composition, the liniment of the present invention can be easily obtained by substituting ketoprofen or the like for a medicinal component of a known liniment and blending a UV blocker.
- the preferred embodiments of the base and formulation examples according to each dosage form of the transdermal preparation for external use of the present invention have been described above, but the dosage form and formulation examples are not limited to these, and each component
- the order of blending is not particularly limited.
- the non-steroidal anti-inflammatory analgesic is substituted with 0.1 to 10 parts by weight of the non-steroidal anti-inflammatory analgesic, and the UV By combining 0.01 to 20 parts by weight of the blocking agent, the eye drop or aerosol of the present invention can be obtained.
- an antioxidant may be further added in addition to the above formulation.
- an antioxidant phenol derivatives such as tert-butylhydroxyl-sol, ditert-butylhydroxytoluene, thymol, propyl gallate, tocopherol and its ester derivatives, ascorbic acid and its ester derivatives, etc. are preferable. .
- Such antioxidants may be used alone or in combination of two or more.
- the blending amount is not particularly limited, but is preferably 0 to 10% by weight, more preferably 0 to 5% by weight based on the total amount of the preparation.
- Example [0032] Hereinafter, the present invention will be described more specifically based on examples. The present invention is not limited to the following examples. In the following examples, “%” means “% by weight” unless otherwise specified.
- mice (female, 9-11 weeks old) were used as test animals, and each test substance dissolved and prepared in ethanol ⁇ 4 1 tert 1 butyl _ 4 '-methoxydibenzoylmethane (BM-DBM) , Dimethoxybenzylidenedioxoimidazoline lysine propionic acid 2-ethyl hexyl ester (DB—DIH), terephthalylidene 1,3′-dicampha 1,10,10, disulfonic acid (TP—DCS), 2- (4— After applying jetylamino-2-hydroxybenzoyl) benzoic acid n-hexenoreestenole (DHB-BH) ⁇ and 2% ketoprofen (KP) to the auricle, 40 jZc
- BM-DBM Dimethoxybenzylidenedioxoimidazoline lysine propionic acid 2-ethyl hexyl ester
- TP—DCS
- the ear thickness was measured 24 hours after UVA irradiation, and the increase from the ear thickness before the start of the test was calculated.
- the suppression effect of the skin symptoms by the non-immunological mechanism derived from KP at the time of light irradiation of each test substance was the extent to which the increase in ear thickness due to KP could be suppressed, and the level index, ie ear edema for the KP group The inhibition rate (%) was evaluated. The results obtained are shown in Tables 1 and 2.
- This sensitization induction treatment was performed for 3 consecutive days. Sensitization started 5 days after the dispensed tail intravenously 3 H- methyl-thymidine (3 H- TdR) / PBS solution of 20 Ci per example mice were excised auricular lymph nodes after 5 hours. The isolated lymph node was made into a single lymphocyte suspension with a cell strainer, washed twice with PBS, and then left overnight in a 5% triclo mouth acetic acid (TCA) solution at 4 ° C to precipitate DNA. . After suspending the precipitate in 1 mL of 5% TCA solution, the radioactivity was measured with a liquid scintillation counter.
- TCA triclo mouth acetic acid
- the inhibitory effect of the test substance on the above-mentioned skin symptoms derived from KP is based on the degree to which the increase in 3 H-TdR uptake by KP was suppressed, ie, the inhibition rate of 3 H-TdR uptake for the KP group ( %).
- the results obtained are shown in Table 3.
- LLNA LLNA
- skin symptoms were detected by immunological mechanism derived from KP during light irradiation.
- BalbZc mice female, 8-12 weeks old
- acetone-olive oil (4: 1, v / v) or acetone-olive oil physiological saline (3: 1: 1, v) / v) dissolved in 2% test substance and 2% KP
- the UVA was applied to a pinna back and 20JZcm 2 irradiation. This sensitization induction treatment was performed for 3 consecutive days.
- mice auricular lymph nodes were removed and pooled in PBS, and PBS adhering to the removed lymph nodes was thoroughly wiped and the weight was measured.
- the suppressive effect of the test substance on the skin symptom due to the immunological mechanism is an index of how much the increase in the auricular lymph node weight due to the same symptom could be suppressed, that is, the inhibition rate of the increase in the auricular lymph node weight relative to the KP group (% ). The results obtained are shown below
- Styrene-isoprene-styrene block copolymer (SIS5200P: JSR) 16 parts by weight, polyisobutylene 10 parts by weight (L-100: manufactured by ExxonMobil), petroleum resin (Arcon P-70: Araki 11 Chemical Industries) 19 parts by weight, liquid paraffin (Crystor J-35 2: made by Esso Petroleum) 45 parts by weight and synthetic aluminum silicate 1.99 parts by weight, nitrogen gas A dissolved product was obtained by heating and stirring under an atmosphere (step A). The temperature during stirring is 110-200 ° C, and the stirring time is 30-120 minutes.
- step B 3 parts by weight of crotamiton, 4-tert-butyl 4,4-methoxydibenzoylmethane, 2 parts by weight of ketoprofen and 3 parts by weight of menthol were added at a stirring temperature of 110 to 110 parts by weight.
- the mixture was added within a range of 200 ° C. and mixed for 5 to 30 minutes to obtain a plaster base as a uniform dissolved product (step B).
- the base is spread on a silicon-treated polyester film so that the weight is lg per 70 cm 2 , and then covered with a polyester woven cloth, transferred by pressure, and cut into a desired size to obtain the plaster agent of the present invention. It was.
- a plaster base as a uniform mixed solution.
- the obtained base is spread on a polyester film treated with silicon so that the weight is lg per 70 cm 2, and ethyl acetate is diffused with hot air, and then covered with a polyester woven cloth, pressure-transferred, and transferred to a desired film.
- the plasters of the present invention were obtained by cutting into sizes.
- ketoprofen 0.3 parts by weight of ketoprofen and 1 part by weight of 4 tert-butyl-4′-methoxydibenzoylmethane were mixed and dissolved in 0.5 parts by weight of crotamiton to obtain a uniform mixture A.
- 6 parts by weight of sodium polyacrylate, 3 parts by weight of polyacrylic acid, 2 parts by weight of gelatin and 1 part by weight of polybutyl alcohol are mixed and dispersed in 20 parts by weight of glycerin, 5 parts by weight of sorbitol and 59.6 parts by weight of water.
- Dissolved and further synthetic aluminum cinnamate 0.5 parts by weight, amino A uniform kneaded mixture B was obtained by adding 0.1 part by weight of dihydroxyaluminum acetate, 0.3 part by weight of magnesium aluminate metasilicate and 0.2 part by weight of tartaric acid. Next, the mixture A was added to the kneaded product B and mixed to obtain a uniform kneaded product. The obtained kneaded material was spread and applied on a polyester nonwoven fabric, and then a polypropylene film was stuck thereon to obtain the poultice of the present invention.
- a poultice according to the present invention was prepared in the same manner as in Formulation Example 16 with the components and amounts shown in Table 7.
- a part of the mixture was mixed at room temperature or under heating, 6.8 parts by weight of beeswax, 8.1 parts by weight of liquid paraffin and 73.6 parts by weight of white petrolatum were added and heated, and kept at 50-100 ° C. After all the components became a transparent solution, they were uniformly mixed with a homomixer. Then, the ointment of the present invention was obtained by lowering the resulting mixture to room temperature while stirring.
- a swollen product A was obtained by swollen 1.8 parts by weight of carboxyvinyl polymer in 30.2 parts by weight of purified water.
- the lysate B is then added to the swollen A and then 0.9% triethanolamine.
- a gel part of the present invention was obtained by adjusting the pH by adding an amount.
- the cream of the present invention was obtained by mixing the components shown in Table 10 in the blending amounts shown in the same table.
- a transdermal preparation for external use containing a photosensitive non-steroidal anti-inflammatory analgesic skin symptoms due to non-immunological and immunological mechanisms derived from the same component at the time of light irradiation It is possible to exert anti-inflammatory and analgesic effects while more reliably preventing the above, and it is expected to be extremely safe and applied as a medicine.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Birds (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SI200631165T SI1872796T1 (sl) | 2005-02-25 | 2006-02-24 | Transdermalni pripravek za zunanjo uporabo, ki vsebuje nesteroidno protivnetno/analgetično sredstvo |
US11/884,990 US20080317689A1 (en) | 2005-02-25 | 2006-02-24 | Transdermal Preparation for External Use Containing Antiinflammatory/Analgesic Agent |
KR1020077020791A KR101298183B1 (ko) | 2005-02-25 | 2006-02-24 | 비스테로이드계 소염 진통제를 함유하는 외용 경피 제제 |
JP2007504809A JP5075622B2 (ja) | 2005-02-25 | 2006-02-24 | 非ステロイド系消炎鎮痛剤を含有する外用経皮製剤 |
PL06714545T PL1872796T3 (pl) | 2005-02-25 | 2006-02-24 | Preparat przezskórny do stosowania zewnętrznego zawierający niesteroidowy lek przeciwzapalny/przeciwbólowy |
DK06714545.8T DK1872796T3 (da) | 2005-02-25 | 2006-02-24 | Transdermal præparat til udvendig brug med et non-steroid antiinflammatorisk/analgetisk middel |
EP06714545A EP1872796B1 (en) | 2005-02-25 | 2006-02-24 | Transdermal preparation for external use containing nonsteroidal antiinflammatory/analgesic agent |
HK08101695.8A HK1112719A1 (en) | 2005-02-25 | 2008-02-15 | Transdermal preparation for external use containing nonsteroidal antiinflammatory/analgesic agent |
US12/769,870 US20100311700A1 (en) | 2005-02-25 | 2010-04-29 | Transdermal preparation for external use containing nonsterioidal antiinflammatory/analgesic agent |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005050991 | 2005-02-25 | ||
JP2005-050991 | 2005-02-25 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US88499007A Continuation | 2005-02-25 | 2007-08-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006090833A1 true WO2006090833A1 (ja) | 2006-08-31 |
Family
ID=36927466
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/303406 WO2006090833A1 (ja) | 2005-02-25 | 2006-02-24 | 非ステロイド系消炎鎮痛剤を含有する外用経皮製剤 |
Country Status (13)
Country | Link |
---|---|
US (2) | US20080317689A1 (ja) |
EP (1) | EP1872796B1 (ja) |
JP (1) | JP5075622B2 (ja) |
KR (1) | KR101298183B1 (ja) |
CY (1) | CY1112111T1 (ja) |
DK (1) | DK1872796T3 (ja) |
ES (1) | ES2370511T3 (ja) |
HK (1) | HK1112719A1 (ja) |
PL (1) | PL1872796T3 (ja) |
PT (1) | PT1872796E (ja) |
SI (1) | SI1872796T1 (ja) |
TW (1) | TWI403333B (ja) |
WO (1) | WO2006090833A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008133272A1 (ja) | 2007-04-23 | 2008-11-06 | Hisamitsu Pharmaceutical Co., Inc. | 貼付剤 |
JP2015531374A (ja) * | 2012-09-27 | 2015-11-02 | アケリオス セラピューティクス,インコーポレーテッド | 局所ケトプロフェン組成物 |
KR20160126981A (ko) | 2014-02-27 | 2016-11-02 | 히사미쓰 세이야꾸 가부시키가이샤 | 케토프로펜 함유 폴티스 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013084995A1 (ja) * | 2011-12-07 | 2013-06-13 | 久光製薬株式会社 | 貼付剤 |
WO2014159798A1 (en) | 2013-03-13 | 2014-10-02 | Avery Dennison Corporation | Improving adhesive properties |
JP2023513668A (ja) | 2020-02-05 | 2023-04-03 | マレル・サーモン・アクティエセルスカブ | 箱からストラップを取り外すための装置、システム、および方法 |
CN113524933B (zh) * | 2021-08-09 | 2023-05-30 | 湖北金德包装有限公司 | 一种改性醇酸树脂的制备方法及其在油墨中的应用 |
CN113652117B (zh) * | 2021-09-07 | 2022-12-13 | 廊坊市安鼎新材料科技有限公司 | 一种环保油墨及其在印刷工艺方法中的应用 |
CN115322099B (zh) * | 2022-07-27 | 2024-04-02 | 五邑大学 | 萘普生-肉桂酸衍生物及其在制备治疗lps诱导炎症的药物中的应用 |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5399316A (en) | 1977-02-04 | 1978-08-30 | Sanpo Seiyaku Kk | Stbilyzing method of leserpine preparation |
JPS5622711A (en) | 1979-08-01 | 1981-03-03 | Pola Chem Ind Inc | Cosmetic prevented from photooxidizing |
JPS60155111A (ja) | 1983-10-20 | 1985-08-15 | Hisamitsu Pharmaceut Co Inc | 安定なケトプロフェン含有外用経皮製剤 |
WO1996008245A1 (fr) * | 1994-09-16 | 1996-03-21 | Hisamitsu Pharmaceutical Co., Inc. | Pansement a usage externe |
JPH09169658A (ja) | 1995-12-19 | 1997-06-30 | Pola Chem Ind Inc | 抗炎症皮膚外用剤 |
JP2000136122A (ja) | 1998-10-28 | 2000-05-16 | Kose Corp | 皮膚外用剤 |
WO2001068061A1 (fr) | 2000-03-17 | 2001-09-20 | Hisamitsu Pharmaceutical Co., Inc. | Preparation adhesive protegeant des uv |
WO2004098575A1 (ja) * | 2003-05-07 | 2004-11-18 | Hisamitsu Pharmaceutical Co., Inc. | 紫外線遮蔽性貼付剤 |
WO2005023307A1 (ja) * | 2003-09-03 | 2005-03-17 | Hisamitsu Pharmaceutical Co., Inc. | 非ステロイド系消炎鎮痛剤を含有する外用経皮製剤 |
WO2005063215A1 (ja) * | 2003-12-26 | 2005-07-14 | Hisamitsu Pharmaceutical Co., Inc. | 消炎鎮痛外用剤 |
WO2005104825A2 (en) * | 2004-04-27 | 2005-11-10 | Litter Revolution, Inc. | Cat litter device |
WO2005123136A1 (ja) * | 2004-06-15 | 2005-12-29 | Hisamitsu Pharmaceutical Co., Inc. | 消炎鎮痛外用剤 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2544180C2 (de) * | 1975-10-03 | 1984-02-23 | Merck Patent Gmbh, 6100 Darmstadt | Lichtschutzmittel für kosmetische Zwecke |
DE69228313T2 (de) * | 1991-08-30 | 1999-09-23 | Hisamitsu Pharmaceutical Co., Inc. | Entzündungshemmendes, analgetisches pflaster |
JP3661706B2 (ja) * | 1993-10-28 | 2005-06-22 | 三省製薬株式会社 | 皮膚外用剤 |
KR20010013377A (ko) * | 1997-06-04 | 2001-02-26 | 데이비드 엠 모이어 | 마일드한 잔류성 항균 조성물 |
US5989528A (en) * | 1998-07-30 | 1999-11-23 | The Procter & Gamble Company | Sunscreen compositions |
US6967023B1 (en) * | 2000-01-10 | 2005-11-22 | Foamix, Ltd. | Pharmaceutical and cosmetic carrier or composition for topical application |
FR2818127B1 (fr) * | 2000-12-18 | 2004-03-12 | Oreal | Composition filtrante photostable contenant un filtre du type derive du dibenzoylmethane et un compose 4,4-diarylbutadiene |
GB0322342D0 (en) * | 2003-09-23 | 2003-10-22 | Gamble Reed | Skin patch |
TWI414320B (zh) * | 2004-05-13 | 2013-11-11 | Hisamitsu Pharmaceutical Co | 含有非類固醇系消炎鎮痛劑之外用經皮製劑 |
-
2006
- 2006-02-24 ES ES06714545T patent/ES2370511T3/es active Active
- 2006-02-24 DK DK06714545.8T patent/DK1872796T3/da active
- 2006-02-24 TW TW095106563A patent/TWI403333B/zh active
- 2006-02-24 KR KR1020077020791A patent/KR101298183B1/ko active IP Right Grant
- 2006-02-24 WO PCT/JP2006/303406 patent/WO2006090833A1/ja active Application Filing
- 2006-02-24 PL PL06714545T patent/PL1872796T3/pl unknown
- 2006-02-24 JP JP2007504809A patent/JP5075622B2/ja active Active
- 2006-02-24 EP EP06714545A patent/EP1872796B1/en active Active
- 2006-02-24 SI SI200631165T patent/SI1872796T1/sl unknown
- 2006-02-24 PT PT06714545T patent/PT1872796E/pt unknown
- 2006-02-24 US US11/884,990 patent/US20080317689A1/en not_active Abandoned
-
2008
- 2008-02-15 HK HK08101695.8A patent/HK1112719A1/xx unknown
-
2010
- 2010-04-29 US US12/769,870 patent/US20100311700A1/en not_active Abandoned
-
2011
- 2011-12-02 CY CY20111101190T patent/CY1112111T1/el unknown
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5399316A (en) | 1977-02-04 | 1978-08-30 | Sanpo Seiyaku Kk | Stbilyzing method of leserpine preparation |
JPS5622711A (en) | 1979-08-01 | 1981-03-03 | Pola Chem Ind Inc | Cosmetic prevented from photooxidizing |
JPS60155111A (ja) | 1983-10-20 | 1985-08-15 | Hisamitsu Pharmaceut Co Inc | 安定なケトプロフェン含有外用経皮製剤 |
WO1996008245A1 (fr) * | 1994-09-16 | 1996-03-21 | Hisamitsu Pharmaceutical Co., Inc. | Pansement a usage externe |
JPH09169658A (ja) | 1995-12-19 | 1997-06-30 | Pola Chem Ind Inc | 抗炎症皮膚外用剤 |
JP2000136122A (ja) | 1998-10-28 | 2000-05-16 | Kose Corp | 皮膚外用剤 |
WO2001068061A1 (fr) | 2000-03-17 | 2001-09-20 | Hisamitsu Pharmaceutical Co., Inc. | Preparation adhesive protegeant des uv |
WO2004098575A1 (ja) * | 2003-05-07 | 2004-11-18 | Hisamitsu Pharmaceutical Co., Inc. | 紫外線遮蔽性貼付剤 |
WO2005023307A1 (ja) * | 2003-09-03 | 2005-03-17 | Hisamitsu Pharmaceutical Co., Inc. | 非ステロイド系消炎鎮痛剤を含有する外用経皮製剤 |
WO2005063215A1 (ja) * | 2003-12-26 | 2005-07-14 | Hisamitsu Pharmaceutical Co., Inc. | 消炎鎮痛外用剤 |
WO2005104825A2 (en) * | 2004-04-27 | 2005-11-10 | Litter Revolution, Inc. | Cat litter device |
WO2005123136A1 (ja) * | 2004-06-15 | 2005-12-29 | Hisamitsu Pharmaceutical Co., Inc. | 消炎鎮痛外用剤 |
Non-Patent Citations (9)
Title |
---|
GERBERICK ET AL., FOOD CHEM. TOXICOL., vol. 27, 1989, pages 813 - 819 |
IDEMITSU T.: "Hikari Sesshoku Hifuen", THE ALLERGY IN PRACTICE, vol. 15, no. 9, 1995, pages 620 - 623, XP003004571 * |
KAMIDE R.: "DRUG-INDUCED PHOTOSENSITIVITY -AN UPDATE-", PHOTOMED. PHOTOBIOL., vol. 21, 1999, pages 9 - 10, XP003004573 * |
NIHON HIFUKAGAKKAIZASSHI, vol. 113, no. 4, 2003, pages 405 - 411 |
PHOTOCHEMISTRY AND PHOTOBIOLOGY, vol. 73, no. 2, 2001, pages 119 - 27 |
RADSCHUWEIT A. ET AL.: "UV-Induces Formation of Hydrogen Peroxide Based on the Photochemistry of Ketoprofen", PHOTOCHEM. PHOTOBIOL., vol. 73, no. 2, 2001, pages 119 - 127, XP002985755 * |
SATO ET AL., NISHINIHON HIFUKA, vol. 42, 1980, pages 831 - 837 |
See also references of EP1872796A4 |
YAMAZAKI F. ET AL.: "Non-Steroid-kei Shoen Chintsuzai no Kodokusei, Hikari Kansano Oyobi Jizokusei Kosen Kabin ni Taisuru Kento", NITIKAWA KAISHI, vol. 113, no. 4, 2002, pages 405 - 411, XP003004572 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008133272A1 (ja) | 2007-04-23 | 2008-11-06 | Hisamitsu Pharmaceutical Co., Inc. | 貼付剤 |
JP2015531374A (ja) * | 2012-09-27 | 2015-11-02 | アケリオス セラピューティクス,インコーポレーテッド | 局所ケトプロフェン組成物 |
KR20160126981A (ko) | 2014-02-27 | 2016-11-02 | 히사미쓰 세이야꾸 가부시키가이샤 | 케토프로펜 함유 폴티스 |
US9707194B2 (en) | 2014-02-27 | 2017-07-18 | Hisamitsu Pharmaceutical Co., Inc. | Ketoprofen-containing poultice |
Also Published As
Publication number | Publication date |
---|---|
EP1872796B1 (en) | 2011-09-21 |
EP1872796A1 (en) | 2008-01-02 |
PT1872796E (pt) | 2011-11-03 |
KR101298183B1 (ko) | 2013-08-20 |
US20080317689A1 (en) | 2008-12-25 |
HK1112719A1 (en) | 2008-09-12 |
JP5075622B2 (ja) | 2012-11-21 |
PL1872796T3 (pl) | 2012-01-31 |
JPWO2006090833A1 (ja) | 2008-07-24 |
DK1872796T3 (da) | 2011-10-17 |
TWI403333B (zh) | 2013-08-01 |
ES2370511T3 (es) | 2011-12-19 |
US20100311700A1 (en) | 2010-12-09 |
TW200640491A (en) | 2006-12-01 |
SI1872796T1 (sl) | 2011-12-30 |
CY1112111T1 (el) | 2015-11-04 |
EP1872796A4 (en) | 2009-08-26 |
KR20070104933A (ko) | 2007-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5551630B2 (ja) | 非ステロイド系消炎鎮痛剤を含有する外用経皮製剤 | |
WO2006090833A1 (ja) | 非ステロイド系消炎鎮痛剤を含有する外用経皮製剤 | |
WO2005123136A1 (ja) | 消炎鎮痛外用剤 | |
JP2007291118A (ja) | ロキソプロフェンナトリウム含有外用製剤の製造方法 | |
WO2013036830A1 (en) | Topical itraconazole formulations and uses thereof | |
US20070280980A1 (en) | Percutaneous Pharmaceutical Preparation for External Use Containing Nonsteroidal Antiinflammatory Analgesic | |
WO2004024155A1 (ja) | 貼付剤 | |
JP4541686B2 (ja) | 非ステロイド系消炎鎮痛剤を含有するテープ剤 | |
TWI294286B (en) | Stabilised topical formulations containing ketoprofen | |
JP4813725B2 (ja) | 鎮痒用外用剤 | |
WO2004112837A1 (ja) | 非ステロイド系消炎鎮痛剤含有外用経皮製剤およびインターロイキン-1α生成抑制剤 | |
JP2006501303A (ja) | ニトロキシド放射線防護製剤および使用法 | |
WO2013040447A2 (en) | Combination therapy with low dosage strength imiquimod and photodynamic therapy to treat actinic keratosis | |
KR101177826B1 (ko) | 비스테로이드계 소염 진통제를 함유하는 외용 경피 제제 | |
WO1999007355A1 (fr) | Preparation contenant de l'idebenone pour administration par voie percutanee | |
JP2008231081A (ja) | ケトプロフェン含有外用剤 | |
JPH10265379A (ja) | ドパミン誘導体含有経皮吸収型製剤 | |
JP2000095687A (ja) | インドメタシン経皮吸収剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2007504809 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11884990 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006714545 Country of ref document: EP Ref document number: 1020077020791 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2006714545 Country of ref document: EP |